Electronic patient diaries in clinical research
|
|
|
- Homer Casey
- 9 years ago
- Views:
Transcription
1 Topics Electronic diaries in Clinical Trials Electronic diaries versus Paper Electronic patient diaries in clinical research Case Study: Novel detection of exacerbations of COPD with patient reported outcome (EXACT-PRO) and Blackberry Isabella Montagna Annamaria Muraro Electronic diaries compliance with regulations Good Clinical Data Management Practices Case study: Forward, CHIESI Farmaceutici The EXACT-PRO questionnaire on BlackBerry Electronic data flow Electronic diaries improvement in study Detection of ECOPD with EXACT-PRO and BlackBerry Conclusions 2
2 Electronic diaries Electronic diaries Subjects diaries are essential in clinical trials that assess occurrence and intensity of symptoms, effects of medication, perceived quality of life. Scientific research has consistently demonstrated that paper diaries make difficult for subjects to comply with the protocol. Otherwise electronic diaries ensure undeniable advantages. By capturing data directly from patients at home, they solve problems often experienced by using paper diaries. What electronic diaries do (and paper diaries don t) Record date and time for each entry automatically Prevent to skip mandatory information Allow to enter only formatted responses Remind automatically to complete Transfer data directly to a central database Make real-time data available to all More pharmaceutical companies worldwide replace paper diaries with electronic ones. 3 4
3 Electronic diaries vs paper Electronic diaries vs paper Electronic diaries Pros Reliable, real time data Reduced missing data Reduced data entry errors High diaries compliance and possibility to monitor it Real time access to study and patient data Integration with clinical databases Cons Training required Familiarity with technology More startup resources needed Paper diaries Pros Established medium Fewer startup resources No training required Easy to produce Cons No reliable date/time stamping (retrospective data entry) Poor quality of data (incomplete, unreadable information, inappropriate responses) Lack of compliance 5 6
4 Electronic diaries compliance with regulations FDA draft Guidance for industry: Electronic Source documentation in Clinical Investigations (January 2011). EMA Expectations from Electronic Source Data and Data Transcribed To Electronic Data Collection Tools in Clinical Trials (September 2010). FDA Guidance for industry: Patient Reported Outcome measures: Use in in Medical Product Development to support Labeling Claims (December 2009). CDISC Leveraging the CDISC standard to facilitate the use of electronic source data within clinical trials (November 2006). US 21 CFR Part 11 Electronic records, electronic signatures (1997) Electronic Diaries - Good Clinical Data Management Practices Electronic diaries collect Patient Reported Outcome to quantify symptoms, disability, emotional states, responses to treatment, Questionnaires are often developed to measure PRO and to quantify the results by established algorithms. Best Practices for epro Use standard, validated questionnaires. Provide detailed instructions to subjects for completion of the electronic diary and conduct appropriate training. Ensure electronic systems are proper validated in compliance with US 21 CFR Part 11. Ensure all processes are in place to assure compliance with regulatory requirements regardind protection and ownership of electronic data. Ensure appropriare level of network security and infrastructure. 7 8
5 Case Study: Forward, CHIESI Farmaceutici Case Study: Forward, CHIESI Farmaceutici Forward is a Clinical Study sponsored by Chiesi Farmaceutici aimed at demonstrating that Foster, a drug registered to cure a severe respiratory pathology called asthma, can be also used to effectively cure another respiratory disease called Chronic Obstructive Pulmonary Disease (COPD). More than 1000 patients involved from 18 countries and treated for 48 weeks. The Clinical Study must satisfy all regulatory authorities and legislation requirements, reaching an effective symptoms control that can be obtained only with a day-by-day report from patients about their health status and frequent visits to the medical centres. To comply with protocol requirements, Chiesi Farmaceutici adopted the solution of electronic diaries. Blackberries were identified as the best technological platform to host the EXACT-PRO questionnaire. 9 10
6 The EXACT-PRO questionnaire The EXACT-PRO questionnaire The EXAcerbations of Chronic Pulmonary Disease Tool (EXACT) is a patient-reported outcome (PRO) measure designed to standardize the method for evaluating the frequency, severity, and duration of acute exacerbations of COPD and chronic bronchitis (AECB) in international studies and clinical trials. The EXACT is a 14-item daily diary to be completed by the patient on the device each evening before bedtime, taking less than 3 minutes to complete. Chiesi customized EXACT-PRO with 4 study specific additional questions. 14 questions Total score - 0 to 100 (higher scores = more severe health status) Domain scores - Scoring 0 to 100 (higher scores = more severe symptoms) - Breathlessness (5 Items) - Cough and Sputum (2 Items) - Chest Symptoms (3 Items) 4 custom questions to record information on rescue medication and study treatment intake
7 EXACT-PRO on BlackBerry EXACT-PRO on BlackBerry The electronic diary on BlackBerry was given to each patient for recording: Daily symptoms and patient status Use of recue medication Compliance of study medication intake. The patients were instructed on how to use the device. Mean patients age: 64 years To facilitate patients in approaching technology, the following measurements were adopted: the clinical study application is the ONLY application to which the users have access only one question per page is displayed. To achieve compliance with the protocol, the following settings were applied: each question must be answered and edited by patients patients can edit today s diary only notifications remind patients to fill in the questionnaire. BlackBerry is one of the most user-friendly device
8 EXACT-PRO on BlackBerry EXACT-PRO on BlackBerry To comply with privacy requirements: patients remain anonymous to Chiesi who only gets data about questionnaire tracking BlackBerry PIN communications are encrypted no data are stored on the device but information are immediately transmitted to the central database and synchronized in a secure Web portal. No need for telephone line (only mobile signal required). Patients health is always controlled by notifications automatically sent to patients and investigators. Notifications to the patients Global (automatically scheduled and delivered) Individual (in case of symptoms worsening) Please remember to call your doctor if your symptoms worsen. Notifications to the investigators Variation in patient s symptoms will trigger an alert that will be sent by or by text
9 Electronic diaries data flow Electronic diaries compliance Subjects Diary Database Diary Web Portal BlackBerries compliance during treatment period EXACT-PRO ALERT Investigator ALERT CHIESI Clinical database Compliance = total days recorded in the BB / total days expected * 100 Mean compliance = 88.64% 17 18
10 Detection of ECOPD with EXACT-PRO and BlackBerry Detection of ECOPD with EXACT-PRO and BlackBerry Electronic diaries but not only +12 pt Threshold Exacerbations of COPD are estimated from persistent increase in daily symptoms that require treatment with systemic steroids, antibiotics and/or hospitalization/er visit. CHIESI Farmaceutici employs electronic diaries on BlackBerry to automatically detect possible ECOPD. A baseline score is set in the device to identify the patient s stable condition. Baseline score = value calculated during the 14 days run-in period when patients are treated with their maintenance therapy. Baseline 1 event as per the EXACT-PRO detection definition Any variation in score of at least 12 points for two consecutives day is considered as significant worsening of the patient s status
11 Detection of ECOPD with EXACT-PRO and BlackBerry Conclusions Electronic diaries improvement in studies More precise data as they are collected daily. Real-time data available both to investigators and sponsor. Daily monitoring of patients health. Daily monitoring of patients compliance in BlackBerry usage and in study medication intake. A - The EXACT-PRO detection threshold matches the diagnosed ECOPD. B - Patient s condition worsens according to symptoms recorded in the BB but no subsequent treatment until further worsening triggering treatment. C - No clear worsening recorded in the BB but patient receives treatment for ECOPD. Corrective actions immediately in place to correct lack of compliance: additional training to patient BlackBerry replacement in case of device malfunction. Savings in questionnaires collections (automatic data transfer to the clinical database) and analysis Savings in the visits with doctors
Your Go-to COPD Guide
Your Go-to COPD Guide Learning how to live with chronic obstructive pulmonary disease (COPD) Inside, you ll learn: COPD facts COPD symptoms and triggers How to talk with your doctor Different treatment
Outcome of Drug Counseling of Outpatients in Chronic Obstructive Pulmonary Disease Clinic at Thawangpha Hospital
Mahidol University Journal of Pharmaceutical Sciences 008; 35(14): 81. Original Article Outcome of Drug Counseling of Outpatients in Chronic Obstructive Pulmonary Disease Clinic at Thawangpha Hospital
Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis What is Idiopathic Pulmonary Fibrosis? Idiopathic pulmonary fibrosis (IPF) is a condition that causes persistent and progressive scarring of the tiny air sacs (alveoli) in
PLAN OF ACTION FOR. Physician Name Signature License Date
PLAN OF ACTION FOR Patient s copy (patient s name) I Feel Well Lignes I feel short directrices of breath: I cough up sputum daily. No Yes, colour: I cough regularly. No Yes I Feel Worse I have changes
Agenda. ARITHMOS Presents: Introduction to epro. EDC and epro integration General Overview. epro and ecrf Integration: a case study
Agenda ARITHMOS Presents: epro and ecrf Integration: a case study Introduction to epro EDC and epro integration General Overview From epro to ipro: Technology trend in Pharma epro EDC integration: A case
1 ALPHA-1. What is Alpha-1? A family history... of lung disease? of liver disease? FOUNDATION
What is Alpha-1? A family history... of lung disease? of liver disease? What you need to know about Alpha-1 Antitrypsin Deficiency 1 ALPHA-1 FOUNDATION What is Alpha-1? Alpha-1 Antitrypsin Deficiency (Alpha-1)
Management of exacerbations in chronic obstructive pulmonary disease in Primary Care
Management of exacerbations in chronic obstructive pulmonary disease in Primary Care Acute exacerbations of chronic obstructive pulmonary disease (COPD) are associated with significant morbidity and mortality.
Prevention of Acute COPD exacerbations
December 3, 2015 Prevention of Acute COPD exacerbations George Pyrgos MD 1 Disclosures No funding received for this presentation I have previously conducted clinical trials with Boehringer Ingelheim. Principal
COPD - Education for Patients and Carers Integrated Care Pathway
Patient NHS COPD - Education for Patients and Carers Integrated Care Pathway Date ICP completed:. Is the patient following another Integrated Care Pathway[s].. / If yes, record which other Integrated Care
Documenting & Coding. Chronic Obstructive Pulmonary Disease (COPD) Presented by: David S. Brigner, MLA, CPC
Documenting & Coding Chronic Obstructive Pulmonary Disease (COPD) Presented by: David S. Brigner, MLA, CPC Sr. Provider Training & Development Consultant Professional Profile David Brigner currently performs
Medication and Devices for Chronic Obstructive Pulmonary Disease (COPD)
Medication and Devices for Chronic Obstructive Pulmonary Disease (COPD) Patients with COPD take a wide variety of medicines to manage their symptoms these include: Inhaled Short Acting Bronchodilators
Using Patient Reported Outcome as Primary or Key Secondary Endpoints-A Regulatory Perspective
Using Patient Reported Outcome as Primary or Key Secondary Endpoints-A Regulatory Perspective Shiling Ruan FDA/CDRH/OSB/DBS Advamed-FDA Statistics Workshop, Gaithersburg, MD Apr 29-30, 2009 1 Acknowledgment
This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
1 ALPHA-1. Am I an Alpha-1 Carrier? FOUNDATION FOUNDATION. Learn how being an Alpha-1 carrier can affect you and your family
Am I an Alpha-1 Carrier? 1 ALPHA-1 FOUNDATION The Alpha-1 Foundation is committed to finding a cure for Alpha-1 Antitrypsin Deficiency and to improving the lives of people affected by Alpha-1 worldwide.
1 ALPHA-1. The Liver and Alpha-1 Antitrypsin Deficiency (Alpha-1) FOUNDATION FOUNDATION. A patient s guide to Alpha-1 liver disease
The Liver and Alpha-1 Antitrypsin Deficiency (Alpha-1) 1 ALPHA-1 FOUNDATION The Alpha-1 Foundation is committed to finding a cure for Alpha-1 Antitrypsin Deficiency and to improving the lives of people
Role of eclinical Systems in FDA Regulated Studies. Jonathan S. Helfgott
Role of eclinical Systems in FDA Regulated Studies Presented by: Jonathan S. Helfgott Operations Research Analyst Office of Scientific Investigations Disclaimer The contents of this presentation are my
Medical Policy An independent licensee of the Blue Cross Blue Shield Association
Afrezza Page 1 of 6 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Afrezza (human insulin) Prime Therapeutics will review Prior Authorization requests Prior Authorization
Guideline for Industry
Guideline for Industry The Extent of Population Exposure to Assess Clinical Safety: For Drugs Intended for Longterm Treatment of Non-Life- Threatening Conditions ICH-E1A March 1995 GUIDELINE FOR INDUSTRY
The Value of A Qualified Outcome Measure Janet Woodcock, M.D.
The Value of A Qualified Outcome Measure Janet Woodcock, M.D. The Critical Path Institute (CPI) Multiple Sclerosis Outcome Assessments Consortium (MSAOC) 1 April 2013 White Oak 1 Overview of Workshop Create
Session 8: Bring Your Own Device (BYOD) - Application in Clinical Trials
Session 8: Bring Your Own Device (BYOD) - Application in Clinical Trials FIFTH ANNUAL PATIENT-REPORTED OUTCOME (PRO) CONSORTIUM WORKSHOP April 29-30, 2014 Silver Spring, MD Co-sponsored by Disclaimer The
COPD and Asthma Differential Diagnosis
COPD and Asthma Differential Diagnosis Chronic Obstructive Pulmonary Disease (COPD) is the third leading cause of death in America. Learning Objectives Use tools to effectively diagnose chronic obstructive
Objectives COPD. Chronic Obstructive Pulmonary Disease (COPD) 4/19/2011
Objectives Discuss assessment findings and treatment for: Chronic Obstructive Pulmonary Disease Bronchitis Emphysema Asthma Anaphylaxis Other respiratory issues Provide some definitions Chronic Obstructive
Guidance for Industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims
Guidance for Industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims U.S. Department of Health and Human Services Food and Drug Administration Center for
Mobile Medical Application Development: FDA Regulation
Mobile Medical Application Development: FDA Regulation Mobile Medical Applications: Current Environment Currently over 100,000 mobile health related applications are available for download; there is an
What Lies Ahead? Trends to Watch: Health Care Product Development in North America
What Lies Ahead? Trends to Watch: Health Care Product Development in North America What Lies Ahead? for 2015 DIA has released its third annual What Lies Ahead? report, providing experts insights into the
James F. Kravec, M.D., F.A.C.P
James F. Kravec, M.D., F.A.C.P Chairman, Department of Internal Medicine, St. Elizabeth Health Center Chair, General Internal Medicine, Northeast Ohio Medical University Associate Medical Director, Hospice
The Liver and Alpha-1. Antitrypsin Deficiency (Alpha-1) 1 ALPHA-1 FOUNDATION
The Liver and Alpha-1 Antitrypsin Deficiency (Alpha-1) 1 ALPHA-1 FOUNDATION What Is Alpha-1 Antitrypsin Deficiency? Alpha-1 is a condition that may result in serious lung disease in adults and/or liver
Hospital to Physician Office to Home: A Respiratory Led Program Across the Continuum of Care
Hospital to Physician Office to Home: A Respiratory Led Program Across the Continuum of Care Charley P. Starnes, RRT, RCP Clinical Respiratory Specialist- COPD Education Important Milestones July 2011-
Data Management and Good Clinical Practice Patrick Murphy, Research Informatics, Family Health International
Data Management and Good Clinical Practice Patrick Murphy,, Family Health International 1 What is GCP? Good Clinical Practice is an international ethical and scientific quality standard for designing,
PCOM Letterhead [Substitute same from participating institution and, of course, change Department, PI, and Co-Investigators]
PCOM Letterhead [Substitute same from participating institution and, of course, change Department, PI, and Co-Investigators] Department of Neuroscience, Physiology and Pharmacology 215-871-6880 PATIENT
Monitoring Clinical Trials with a SAS Risk-Based Approach
Paper DH05 Monitoring Clinical Trials with a SAS Risk-Based Approach Laurie Rose, SAS, Cary, NC USA ABSTRACT With global regulatory encouragement, the life sciences industry is gaining momentum to embrace
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE. Current Step 4 version
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE THE EXTENT OF POPULATION EXPOSURE TO ASSESS CLINICAL
Marilyn Borkgren-Okonek, APN, CCNS, RN, MS Suburban Lung Associates, S.C. Elk Grove Village, IL
Marilyn Borkgren-Okonek, APN, CCNS, RN, MS Suburban Lung Associates, S.C. Elk Grove Village, IL www.goldcopd.com GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE LUNG DISEASE GLOBAL STRATEGY FOR DIAGNOSIS, MANAGEMENT
Quit & Get Fit! Frequently Asked Questions For Personal Trainers (November 2011)
Quit & Get Fit! Frequently Asked Questions For Personal Trainers (November 2011) What is Quit & Get Fit? Quit & Get Fit is an initiative of the Ontario Lung Association, made possible through funding from
Longitudinal Modeling of Lung Function in Respiratory Drug Development
Longitudinal Modeling of Lung Function in Respiratory Drug Development Fredrik Öhrn, PhD Senior Clinical Pharmacometrician Quantitative Clinical Pharmacology AstraZeneca R&D Mölndal, Sweden Outline A brief
SLEEP DISTURBANCE AND PSYCHIATRIC DISORDERS
E-Resource December, 2013 SLEEP DISTURBANCE AND PSYCHIATRIC DISORDERS Between 10-18% of adults in the general population and up to 50% of adults in the primary care setting have difficulty sleeping. Sleep
ASK A DOC. Clinical Trial Update May 28, 2014. Welcome!
ASK A DOC Clinical Trial Update May 28, 2014 Welcome! ASK A DOC CLINICAL TRIAL UPDATE Dr. Gregory Cosgrove PFF Chief Medical Officer Dr. Kevin Flaherty Chairman Steering Committee PFF CCN and PFF Registry
EUROPEAN LUNG FOUNDATION
PULMONARY REHABILITATION understanding the professional guidelines This guide includes information on what the European Respiratory Society and the American Thoracic Society have said about pulmonary rehabilitation.
EU PAS Register Guide
29 March 2016 EMA/613603/2012 (currently ENCePP E-Register of Studies) The EU PAS Register is temporarily hosted on the ENCePP website www.encepp.eu 1. Introduction... 2 2. ENCePP E-Register as a temporary
COPD PROTOCOL CELLO. Leiden
COPD PROTOCOL CELLO Leiden May 2011 1 Introduction This protocol includes an explanation of the clinical picture, diagnosis, objectives and medication of COPD. The Cello way of working can be viewed on
The impact of FDA and EMA guidances regarding Patient Reported Outcomes (PRO) on the drug development and approval process
The impact of FDA and EMA guidances regarding Patient Reported Outcomes (PRO) on the drug development and approval process Wissenschaftliche Prüfungsarbeit zur Erlangung des Titels Master of Drug Regulatory
An Overview of Asthma - Diagnosis and Treatment
An Overview of Asthma - Diagnosis and Treatment Asthma is a common chronic disorder of the airways that is complex and characterized by variable and recurring symptoms, airflow obstruction, bronchial hyperresponsiveness,
Guidance for Industry
Guidance for Industry Electronic Source Data in Clinical Investigations U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for
University of Hawai i Human Studies Program. Guidelines for Developing a Clinical Research Protocol
University of Hawai i Human Studies Program Guidelines for Developing a Clinical Research Protocol Following are guidelines for writing a clinical research protocol for submission to the University of
Exploratory data: COPD and blood eosinophils. David Price: 9.23-9.35am
Exploratory data: COPD and blood eosinophils David Price: 9.23-9.35am Blood Eosinophilia in COPD The reliability and utility of blood eosinophils as a marker of disease burden, healthcare resource utilisation
Bronchodilators in COPD
TSANZSRS Gold Coast 2015 Can average outcomes in COPD clinical trials guide treatment strategies? Long live the FEV1? Christine McDonald Dept of Respiratory and Sleep Medicine Austin Health Institute for
Better Breathing with COPD
Better Breathing with COPD People with Chronic Obstructive Pulmonary Disease (COPD) often benefit from learning different breathing techniques. Pursed Lip Breathing Pursed Lip Breathing (PLB) can be very
epro Integration with Oracle Remote Data Capture
epro Integration with Oracle Remote Data Capture BIAS Congress 27-28 May 2010 Rome (IT) Davide Di Giovine, CROS NT Senior DM & CSV Manager [email protected] AGENDA Changes in handling of clinical
COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency Evaluation of Medicines for Human Use London, 19 July 2007 Doc. Ref: EMEA/27170/2006 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON COMPASSIONATE USE OF MEDICINAL
Measure Information Form (MIF) #275, adapted for quality measurement in Medicare Accountable Care Organizations
ACO #9 Prevention Quality Indicator (PQI): Ambulatory Sensitive Conditions Admissions for Chronic Obstructive Pulmonary Disease (COPD) or Asthma in Older Adults Data Source Measure Information Form (MIF)
COPD It Can Take Your Breath Away www.patientedu.org
written by Harvard Medical School COPD It Can Take Your Breath Away www.patientedu.org What Is COPD? COPD stands for chronic obstructive pulmonary disease. There are 2 major diseases included in COPD:
Sponsor Novartis Pharmaceuticals
Clinical Trial Results Database Page 1 Sponsor Novartis Pharmaceuticals Generic Drug Name Indacaterol Therapeutic Area of Trial Chronic Obstructive Pulmonary Disease (COPD) Indication studied: COPD Study
Inhaler Technique Check
Protocol October 2015 Version 1.3 Table of Contents Service Information... 2 Service objective... 2 Clinical service overview... 2 Documentation... 3 Staff Roles... 3 Facilities to support the program...
Respiratory Clinical Trial Services. the difference is clear. Your respiratory clinical trials partner
Respiratory Clinical Trial Services the difference is clear Your respiratory clinical trials partner Our heritage We at Vitalograph are proud of our 50 year heritage as a world leading respiratory specialist.
Wireless Remote Monitoring System for ASTHMA Attack Detection and Classification
Department of Telecommunication Engineering Hijjawi Faculty for Engineering Technology Yarmouk University Wireless Remote Monitoring System for ASTHMA Attack Detection and Classification Prepared by Orobh
Coventry Health Care of Florida, Inc. Coventry Health Plan of Florida, Inc. Coventry Health and Life Insurance Company Commercial Lines of Business
Coventry Health Care of Florida, Inc. Coventry Health Plan of Florida, Inc. Coventry Health and Life Insurance Company Commercial Lines of Business Quality Management Program 2012 Overview Quality Improvement
3/11/15. COPD Disease Management Tackling the Transition. Objectives. Describe the multidisciplinary approach to inpatient care for COPD patients
Faculty Disclosures COPD Disease Management Tackling the Transition Dr. Cappelluti has no actual or potential conflicts of interest associated with this presentation. Jane Reardon has no actual or potential
NEW RESPIRATORY HEALTH PROGRAM
NEW RESPIRATORY HEALTH PROGRAM Introducing the Medavie Blue Cross Managing Chronic Disease Program Medavie Blue Cross is proud to announce our innovative new approach to managing chronic disease- the first
TravelCare Medical Questionnaire Instruction Sheet for Agents
TravelCare Medical Questionnaire Instruction Sheet for Agents Helpful Reminders: We want your client to be comfortable when completing the Medical Questionnaire. It is important that you remind your client
ST. MICHAEL S HOSPITAL Guidelines for Reporting Serious Adverse Events / Unanticipated Problems to the SMH Research Ethics Board (REB) July 09, 2014
ST. MICHAEL S HOSPITAL Guidelines for Reporting Serious Adverse Events / Unanticipated Problems to the SMH Research Ethics Board (REB) July 09, 2014 1. Introduction The St. Michael s Hospital (SMH) REB
Compare the physiologic responses of the respiratory system to emphysema, chronic bronchitis, and asthma
Chapter 31 Drugs Used to Treat Lower Respiratory Disease Learning Objectives Describe the physiology of respirations Compare the physiologic responses of the respiratory system to emphysema, chronic bronchitis,
Quality Management in Clinical Trials
CLINICAL CASE STUDY SERIES Quality Management in Clinical Trials Clinical trials are conducted to collect the data necessary to provide information for academia, industry, and regulators to make decisions
CMS National Coverage Policy
LCD ID Number L32764 LCD Title Pulmonary Rehabilitation (PR) Programs Contractor s Determination Number L32764 AMA CPT/ADA CDT Copyright Statement CPT only copyright 2002-2011 American Medical Association.
Using Social Media in Research: Regulatory and IRB Considerations
Using Social Media in Research: Regulatory and IRB Considerations Webinar Housekeeping Questions & Answers Feel free to submit questions at any point during the webinar using the chat box on your webinar
Medicare Pulmonary Rehabilitation (PR) Benefit Frequently Asked Questions June 2010 (Latest Updates: December 18, 2013 and February 12, 2014)
Medicare Pulmonary Rehabilitation (PR) Benefit Frequently Asked Questions June 2010 (Latest Updates: December 18, 2013 and February 12, 2014) Coverage Criteria Q. CMS has stated that only patients with
Guidance for Industry
Guidance for Industry IND Exemptions for Studies of Lawfully Marketed Drug or Biological Products for the Treatment of Cancer U.S. Department of Health and Human Services Food and Drug Administration Center
ASTHMA IN INFANTS AND YOUNG CHILDREN
ASTHMA IN INFANTS AND YOUNG CHILDREN What is Asthma? Asthma is a chronic inflammatory disease of the airways. Symptoms of asthma are variable. That means that they can be mild to severe, intermittent to
Licensed Healthcare Providers Guidelines for Telemedicine Using the MyDocNow Platform
Contents 1. Scope of These Guidelines... 2 2. What is Telemedicine?... 2 3. Introduction... 3 4. What Are the Benefits of Telemedicine?... 3 5. Frequently Asked Questions Physician Care and Treatment...
BEACON HEALTH STRATEGIES, LLC TELEHEALTH PROGRAM SPECIFICATION
BEACON HEALTH STRATEGIES, LLC TELEHEALTH PROGRAM SPECIFICATION Providers contracted for the telehealth service will be expected to comply with all requirements of the performance specifications. Additionally,
ROLE OF THE RESEARCH COORDINATOR
Clinical and Translational Science Institute / CTSI at the University of California, San Francisco Welcome to Online Training for Clinical Research Coordinators ROLE OF THE RESEARCH COORDINATOR Data Collection
Medicare Part A. Pulmonary Rehab Program Services Web-Based Training February 25, 2010 - Q & As
Pulmonary Rehab Program Services Web-Based Training February 25, 2010 - Q & As The following are the question and answers from the Pulmonary Rehabilitation Program Services web-based training which was
GENERAL INFORMATION. Adverse Event (AE) Definition (ICH GUIDELINES E6 FOR GCP 1.2):
Make copies of the blank SAE report form as needed. Retain originals with confirmation of all information faxed to DMID Pharmacovigilance Group Clinical Research Operations and Management Support (CROMS
COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINE FOR THE CONDUCT OF POST-MARKETING SURVEILLANCE STUDIES OF VETERINARY MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Information Technology EMEA/CVMP/044/99-FINAL COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINE FOR THE CONDUCT
Efficient Asset Tracking: From Manual to Automated
White Paper Efficient Asset Tracking: From Manual to Automated Asset Tracking Overview: Asset Tracking Basics: The Fixed Asset Register Managing a Fixed Asset Register Asset Identification Technologies
Telehealth Solutions Enhance Health Outcomes and Reduce Healthcare Costs
Text for a pull out can go heretext for a pull out can go heretext for a pull out can go Text for a pull out can go here Text for a pull out can go here Telehealth Solutions Enhance Health Outcomes and
J of Evolution of Med and Dent Sci/ eissn- 2278-4802, pissn- 2278-4748/ Vol. 3/ Issue 65/Nov 27, 2014 Page 13575
EFFECT OF BREATHING EXERCISES ON BIOPHYSIOLOGICAL PARAMETERS AND QUALITY OF LIFE OF PATIENTS WITH COPD AT A TERTIARY CARE CENTRE Sudin Koshy 1, Rugma Pillai S 2 HOW TO CITE THIS ARTICLE: Sudin Koshy, Rugma
Welcome to the training on the TransCelerate approach to Risk-Based Monitoring. This course will take you through five modules of information to
Welcome to the training on the TransCelerate approach to Risk-Based Monitoring. This course will take you through five modules of information to introduce you to the concepts behind risk-based monitoring,
EVALUATION OF AUTOMATIC CLASS III DESIGNATION FOR STUDIO on the Cloud Data Management Software DECISION SUMMARY
A. DEN Number: DEN140016 EVALUATION OF AUTOMATIC CLASS III DESIGNATION FOR STUDIO on the Cloud Data Management Software B. Purpose for Submission: DECISION SUMMARY De novo request for adjunct data management
Principal Investigator and Sub Investigator Responsibilities
Principal Investigator and Sub Investigator Responsibilities I. Purpose To define the roles and responsibilities of Principal Investigators conducting research at GRU. II. Definition The term Principal
Supplement to the Guidance for Electronic Data Capture in Clinical Trials
Supplement to the Guidance for Electronic Data Capture in Clinical Trials January 10, 2012 Drug Evaluation Committee, Japan Pharmaceutical Manufacturers Association Note: The original language of this
Frequently Asked Questions about Crab Asthma
Frequently Asked Questions about Crab Asthma 1. Occupational asthma to snow crab: What is it? Asthma is a condition that results in breathing difficulties. These breathing difficulties occur when the breathing
Chronic Obstructive Pulmonary Disease (COPD) Programme
Integrated Care Pathway Chronic Obstructive Pulmonary Disease (COPD) Programme Patient Handbook Contents Preface... 1 What is COPD?... 3 What causes COPD?... 4 - Smoking... 4 - Air pollution... 4 - The
Development of Case Report Forms
Development of Case Report Forms Introduction to the Principles and Practice of Clinical Research February 12, 2013 Diane St. Germain, RN, MS Nurse Consultant Division of Cancer Prevention National Cancer
Disease Management Identifications and Stratification Health Risk Assessment Level 1: Level 2: Level 3: Stratification
Disease Management UnitedHealthcare Disease Management (DM) programs are part of our innovative Care Management Program. Our Disease Management (DM) program is guided by the principles of the UnitedHealthcare
Subject: No. Page PROTOCOL AND CASE REPORT FORM DEVELOPMENT AND REVIEW Standard Operating Procedure
703 1 of 11 POLICY The Beaumont Research Coordinating Center (BRCC) will provide advice to clinical trial investigators on protocol development, content and format. Upon request, the BRCC will review a
COPD. Information brochure for chronic obstructive pulmonary disease.
COPD Information brochure for chronic obstructive pulmonary disease. CONTENTS What does COPD mean?...04 What are the symptoms of COPD?...06 What causes COPD?...09 Treating COPD...10 Valve therapy in COPD...12
